Anti-Inflammatory Effects of Resveratrol, Curcumin and Simvastatin in Acute Small Intestinal Inflammation by Bereswill, Stefan et al.
Anti-Inflammatory Effects of Resveratrol, Curcumin and
Simvastatin in Acute Small Intestinal Inflammation
Stefan Bereswill
1, Melba Mun ˜oz
1, Andre ´ Fischer
1, Rita Plickert
1, Lea-Maxie Haag
1, Bettina Otto
1, Anja A.
Ku ¨hl
2, Christoph Loddenkemper
2, Ulf B. Go ¨bel
1, Markus M. Heimesaat
1*
1Institut fu ¨r Mikrobiologie und Hygiene, Charite ´ – Universita ¨tsmedizin Berlin, Berlin, Germany, 2Institut fu ¨r Pathologie, Charite ´ - Universita ¨tsmedizin Berlin, Berlin,
Germany
Abstract
Background: The health beneficial effects of Resveratrol, Curcumin and Simvastatin have been demonstrated in various
experimental models of inflammation. We investigated the potential anti-inflammatory and immunomodulatory
mechanisms of the above mentioned compounds in a murine model of hyper-acute Th1-type ileitis following peroral
infection with Toxoplasma gondii.
Methodology/Principal Findings: Here we show that after peroral administration of Resveratrol, Curcumin or Simvastatin,
mice were protected from ileitis development and survived the acute phase of inflammation whereas all Placebo treated
controls died. In particular, Resveratrol treatment resulted in longer-term survival. Resveratrol, Curcumin or Simvastatin
treated animals displayed significantly increased numbers of regulatory T cells and augmented intestinal epithelial cell
proliferation/regeneration in the ileum mucosa compared to placebo control animals. In contrast, mucosal T lymphocyte
and neutrophilic granulocyte numbers in treated mice were reduced. In addition, levels of the anti-inflammatory cytokine IL-
10 in ileum, mesenteric lymph nodes and spleen were increased whereas pro-inflammatory cytokine expression (IL-23p19,
IFN-c, TNF-a, IL-6, MCP-1) was found to be significantly lower in the ileum of treated animals as compared to Placebo
controls. Furthermore, treated animals displayed not only fewer pro-inflammatory enterobacteria and enterococci but also
higher anti-inflammatory lactobacilli and bifidobacteria loads. Most importantly, treatment with all three compounds
preserved intestinal barrier functions as indicated by reduced bacterial translocation rates into spleen, liver, kidney and
blood.
Conclusion/Significance: Oral treatment with Resveratrol, Curcumin or Simvastatin ameliorates acute small intestinal
inflammation by down-regulating Th1-type immune responses and prevents bacterial translocation by maintaining gut
barrier function. These findings provide novel and potential prophylaxis and treatment options of patients with
inflammatory bowel diseases.
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Introduction
Several nutritional compounds are the focus of public attention
because of their potential beneficial health effects. Some
compounds derived from plants and herbs (e.g. Resveratrol,
Curcumin) have been proven effective in traditional medicine as
herbal remedies for inflammatory disorders such as hepatitis,
arthritis, and colitis [1]. Both, Resveratrol and Curcumin also
exert pharmacological effects in various experimental models of
acute and chronic inflammation [1]. In addition, some pharma-
ceutical compounds (e.g. statins) have shown to possess anti-
inflammatory, immuno-modulatory properties apart from their
original indication for disease treatment [2].
Resveratrol (3,5,49-trihydoxy-trans-stilbene) is a polyphenol
found in grape skins and red wine. Resveratrol has been reported
to exert multiple health-promoting benefits such as anti-inflam-
matory, anti-oxidant, anti-tumor, anti-platelet aggregation, anti-
aging and anti-atherogenic effects [3]. Anti-inflammatory proper-
ties of Resveratrol have been described in several diseases such as
arthritis [4], pancreatitis [5], and experimental colitis [6].
Curcumin is a polyphenol derived from the root of the turmeric
plant Curcuma longa and responsible for the yellow-orange color and
the spicy taste of curries [7]. Curcumin exerts anti-infectious, anti-
tumor, and anti-inflammatory properties [8]. Preventive as well as
therapeutic anti-inflammatory effects of Curcumin treatment have
been observed in various animal models [9].
Simvastatin belongs to the class of cholesterol-lowering statins
that are widely used to reduce cardiovascular morbidity and
mortality in patients with or without coronary artery disease [10].
Statins have been also proposed to exert anti-inflammatory effects
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15099that are not directly related to their cholesterol-lowering activity
[2] by interfering with endothelial adhesion and leukocyte
migration to sites of inflammation [11].
Within eight to ten days following peroral infection with the
parasite Toxoplasma (T.) gondii, susceptible mice develop severe
small intestinal necrosis (pan-ileitis), induced by IL-23 [12] and
mediated by a strong Th1-type immune response with a
subsequent storm of pro-inflammatory cytokines including IL-12,
IFN-c, TNF-a, and nitric oxide (NO) [13]. Furthermore,
inflammation triggers characteristic quantitative as well as
qualitative ileum flora shifts [14,15]. We demonstrated earlier
that luminal concentrations of commensal Gram-negative bacteria
such as E. coli increase and aggravate ileitis development through
TLR4-dependent signaling pathways [15]. Moreover, commensal
gut bacteria translocate through the leaky epithelial barrier into
the intestinal submucosa and spread to adjacent organs through
blood or lymphatic vessels leading to sepsis and multi-organ failure
[12]. Taken together, the Th1-type immunopathology in the T.
gondii-mediated ileitis model is triggered by the commensal
microbiota and thus resembles the immunological key features of
acute episodes in inflammatory bowel disease (IBD) such as
Crohn’s disease (ileitis terminalis) in humans. However, experi-
mental models of small intestinal inflammation are scarce and
most of the experimental IBD models assess the large intestine.
Given that Resveratrol, Curcumin or Simvastatin have been
shown to suppress immune responses, we investigated the
immuno-modulatory effects of these compounds in this well
characterized model of ileitis. Our results showed the anti-
inflammatory and immuno-modulating properties of all three
compounds. Amelioration of ileitis was accompanied by reduced
immunopathology and an integral gut barrier function that
prevented bacterial translocation. These findings provide novel
potential therapeutic options for patients during the acute episodes
of Crohn’s disease.
Results
Resveratrol treatment prolongs survival in an acute ileitis
model
To investigate the beneficial effects of Resveratrol, Curcumin,
and Simvastatin on small intestinal inflammation, we infected
C57BL/10 mice with T. gondii and compared survival rates
between treated and Placebo control mice. Whereas all untreated
control mice had died at day 11 p.i., 20% of Curcumin- and 40%
of Simvastatin- or Resveratrol-treated animals survived the acute
phase of inflammation (Fig. 1). Furthermore, Resveratrol treated
mice displayed significantly higher survival rates until the end of
the experiment as compared to Placebo controls (40% survival, 19
days post infection; p,0.005, Kaplan Meier analysis; Fig. 1).
Thus, Resveratrol treatment prolongs survival in our hyper-acute
ileitis model.
Simvastatin, Curcumin, and Resveratrol ameliorate acute
small intestinal inflammation
Mice orally treated with Simvastatin, Resveratrol or Curcumin
displayed significantly less macroscopic signs of intestinal inflam-
mation. Within 8 days p.i., Placebo control mice had lost
approximately 15% of their initial body weight whereas mice
treated with either compound displayed significant less weight loss
(between 9 and 11%; p,0.005) (Fig. 2 A). Given that ileal
inflammation is accompanied by a significant shortening of the
upper intestinal tract, we determined the lengths of the small
intestine between treated and control animals. T. gondii infection
resulted in less significant shortening of the small intestinal length
in treated mice compared with the Placebo group (16–18% vs.
22% respectively; p,0.05) (Fig. 2 B). Moreover, animals treated
with Simvastatin, Resveratrol or Curcumin displayed only mild
signs of inflammation in their ileal mucosa including edema and
cell-free exudate into the lumen but maintained an intact
epithelium. In contrast, severe ileal inflammation including initial
necrosis was observed in the control group (p,0.0001) (Fig. 2 C).
Thus, oral treatment of Simvastatin, Resveratrol or Curcumin
ameliorates acute small intestinal T. gondii-induced inflammation.
To examine whether differences in T. gondii loads within the
ileum might have contributed to the beneficial effects observed
after peroral treatment with Simvastatin, Resveratrol or Curcu-
min, we assessed T. gondii DNA concentrations in treated and
untreated mice. Neither the amount of T. gondii DNA nor the
number of parasitophorous vacuoles containing T. gondii tachy-
zoites in the ileum differed significantly between treated and
Placebo groups at the same time point (data not shown).
Immuno-modulatory effects of Simvastatin, Resveratrol
or Curcumin treatment in the mucosa in situ during acute
ileitis
To further elucidate potential immuno-modulatory mechanisms
by which the compounds under investigation exerted their
beneficial effects, we assessed the number of several immune cell
subsets in the ileal mucosa and submucosa of treated vs control
mice with ileitis (Fig. 3 A–D). Because acute inflammation in T.
gondii ileitis is T-cell driven and Th1 dominated [13], and there is
strong evidence that regulatory T cells accumulate at inflamed
tissue sites in IBD patients [16], we quantified CD3
+ and FOXP3
+
T cells in the ileum in situ by immunohistochemistry. Ileitis resulted
in a significant accumulation of CD3
+ cells within the ileum
mucosa and submucosa (p,0.000001 vs naı ¨ve mice) (Fig. 3 A).
This increase of T lymphocytes, however, was significantly less
pronounced in mice treated either with Resveratrol or Curcumin
(p,0.05 vs. Placebo) (Fig. 3 A). Furthermore acute ileitis was
accompanied by a 50% reduction of FOXP3
+ T lymphocytes in
the ileum on d8 p.i. (p,0.00001 as compared to non-infected,
naı ¨ve animals, Fig. 3 B). Most importantly, mice from either the
Simvastain, Resveratrol or Curcumin treatment group displayed
20–30% higher FOXP3
+ cell numbers as compared to Placebo
controls with ileitis on d8 p.i. (p,0.05-0.00001) (Fig. 3 B).
Figure 1. Survival rates of mice treated with Placebo (n=23),
Simvastain (n=5), Resveratrol (n=5) or Curcumin (n=6) from
d-2 until d8 p.i.. Mortality of animals was monitored daily until d19
p.i.. Significance levels (as compared with Placebo controls) were
determined by Kaplan-Meier analysis.
doi:10.1371/journal.pone.0015099.g001
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innate immune cells during acute ileitis development, we
investigated the recruitment of myeloperoxidase-7
+ (MPO-7
+)
cells in the small intestinal lamina propria of both treated and
control mice in the acute phase of disease (Fig. 3 C). On d8 p.i., a
more than 5-fold increase in MPO-7
+ cells was observed within
the ileum of Placebo control animals compared to naı ¨ve mice,
which were non-infected and untreated (p,0.005). However,
Simvastatin, Resveratrol or Curcumin treated mice displayed 25–
50% fewer MPO-7
+ cells as compared to Placebo controls
(p,0.05) (Fig. 3 C).
In addition, we evaluated cell proliferation and regeneration in
ileal sections on d8 p.i. using Ki-67, an antibody that recognizes a
nuclear cell proliferation-associated antigen expressed in all active
stages of the cell cycle [17]. After T. gondii infection, Ki-67
+ cell
numbers increased significantly as compared to naı ¨ve mice
(p,0.00001) (Fig. 3 D). Mice treated with either Resveratrol or
Curcumin, however, displayed 50% more Ki-67
+ cells than
Simvastatin- or Placebo treated animals on d8 p.i. (p,0.005).
Taken together, treatment with Simvastatin, Resveratrol or
Curcumin modulates small intestinal immune cell responses
during acute ileitis by decreasing CD3
+ and MPO7
+ cell
accumulation but increasing FOXP3
+ and Ki-67
+ cell numbers.
Pro- and anti-inflammatory cytokine responses after
peroral treatment of mice with acute ileitis
Given that treated mice were resistant to the development of T.
gondii-induced ileitis compared to untreated mice but T. gondii
DNA concentration in the ileum did not differ significantly
between these groups, we hypothesized that differential pro-
inflammatory cytokine expression profiles within the ilea,
mesenteric lymph nodes (MLNs) or spleens might explain the
reduced immunopathology observed after treatment with the
compounds mentioned above at d8 p.i..
The analysis of mRNA in the ileum in situ revealed that IL-
23p19 (p,0.001), IFN-c (p,0.05), and TNF-a (p,0.01) expres-
sions were significantly down-regulated in Curcumin-treated mice
at d8 p.i. as compared to untreated controls (Fig. 4 A), whereas
Resveratrol treated animals exhibited lower IL-6 ileal mRNA
expression (Fig. 4 B). In addition, IFN-c (p,0.05) and MCP-1
(p,0.05) secretion into ex vivo ileum cultures were significantly
lower after Resveratrol, Curcumin or Simvastatin treatment
compared to Placebo (Fig. 5 A–B). Furthermore, significantly
higher amounts of the anti-inflammatory cytokine IL-10 were
found in the ilea (p,0.01-0.001), MLNs (p,0.01-0.005) and
spleens (p,0.05-0.01) after either treatment regimen compared to
Placebo controls with ileitis (Fig. 6 A–C).
Taken together, our results show that treatment with either
Simvastain, Resveratrol or Curcumin modulates the cytokine
profile within the small intestine which agrees with changes of
immune cell subsets (fewer T cells and neutrophils, more Tregs)
observed in treated mice pointing towards less pro- and more anti-
inflammatory responses.
Reduced pro-inflammatory gut bacterial species in the
small intestine of mice treated with Simvastatin,
Curcumin or Resveratrol
Because we have shown that E. coli overgrowth in the terminal
ileum aggravates T. gondii induced inflammation [14,15], we
compared the composition of the ileum microflora of mice after
treatment with Simvastatin, Curcumin or Resveratrol at d8 p.i..
Cultural analysis demonstrated that the total bacterial load
increased during ileitis, but was significantly reduced by 1 to 2
orders of magnitude in treated mice as compared to Placebo
controls (Fig. 7 A)( p ,0.05-0.0005). A more detailed cultural
analysis revealed that following treatment concentrations of pro-
inflammatory bacterial species such as E. coli (Fig. 7 B) and
enterococci (Fig. 7 C) were significantly reduced by 3.0 – 3.5
(p,0.000001) and 1.0 – 1.5 (p,0.0005) orders of magnitude,
respectively, whereas the potentially anti-inflammatory lactoba-
cilli and bifidobacteria populations were slightly increased by up
to 1.0 log orders (Fig. 7 D)( p ,0.05-0.0005). Counts of
Clostridium and Eubacterium spp. were unaffected after treatment
(data not shown). Interestingly, changes in the ileal flora
Figure 2. Less small intestinal immunopathology after treatment with Simvastain, Resveratrol or Curcumin (8 days after T. gondii
infection). (A) Relative body weight loss of mice after treatment with Placebo (n=8), Simvastain (SIMVA; n=9), Resveratrol (RESVE; n=9) or
Curcumin (CURCU; n=9) from d-2 until d8 p.i. (B) Relative small intestinal shortening of mice after treatment with Placebo (n=13), Simvastain
(SIMVA; n=14), Resveratrol (RESVE; n=12) or Curcumin (CURCU; n=14) from d-2 until d8 p.i. (C) Histopathology of the terminal ileum of mice treated
with Placebo (n=27), Simvastain (SIMVA; n=14), Resveratrol (RESVE; n=12) or Curcumin (CURCU; n=14) from d-2 until d8 p.i.. Mean values, standard
deviations, and significance levels as indicated were determined by the Student’s t test. Data are pooled from at least three independent
experiments.
doi:10.1371/journal.pone.0015099.g002
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Furthermore, a direct antimicrobial effect of Simvastatin,
Resveratrol or Curcumin was ruled out by specific in vitro testing
of the substances in the presence of the highly susceptible
laboratory strain Bacillus subtilis (data not shown). Thus, shifts in
bacterial ileal flora concentrations (lower bacterial loads and less
E. coli overgrowth) in treated mice during ileitis were not due to
direct antimicrobial effects but rather agrees with the observed
macroscopic and microscopic anti-inflammatory effects of the
respective substances.
Figure 3. Quantification of defined cell population in the ileum of mice in situ after treatment with Simvastain, Resveratrol or
Curcumin (8 days after T. gondii infection). The average number of cells positive for (A) CD3, (B) FOXP3, (C) MPO7 (Myeloperoxidase), and (D) Ki-
67 from at least six high power fields (HPF, 4006magnification) per animal were determined microscopically in immunostained ileum sections at d8
p.i. after treatment of mice with Placebo, Simvastain (SIMVA), Resveratrol (RESVE), or Curcumin (CURCU) from d-2 until d8 p.i. and naı ¨ve, uninfected
animals. Numbers of analyzed animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as indicated were
determined by the Student’s t test. Data are pooled from at least three independent experiments.
doi:10.1371/journal.pone.0015099.g003
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Curcumin or (B) Resveratrol from d-2 until d8 p.i. compared to Placebo controls. RT-PCR results of IL-23p19, IFN-c and TNF-a (A) and IL-6
(B) expression from individual mice are expressed as fold changes relative to HPRT mRNA expression (arbitrary units). Numbers of analyzed animals
are given in parentheses. Mean values and significance levels as indicated were determined by the Student’s t test. Data are pooled from at least
three independent experiments.
doi:10.1371/journal.pone.0015099.g004
Figure 5. (A) IFN-c and (B) MCP-1 concentrations (CBA-ELISA) in supernatants of ileum cultures from naı ¨ve, uninfected animals and
mice treated with Simvastatin (SIMVA), Resveratrol (RESVE) or Curcumin (CURCU) from d-2 until d8 p.i. as compared to Placebo
controls (8 days after T. gondii infection). Numbers of analyzed animals are given in parentheses. Mean values, standard errors of the mean, and
significance levels as indicated were determined by the Student’s t test. Data are pooled from at least two independent experiments.
doi:10.1371/journal.pone.0015099.g005
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bacterial translocation during T. gondii-induced ileitis
Since we have recently demonstrated that acute ileitis is
accompanied by translocation of living bacteria from the
commensal gut flora into adjacent organs [15] we lastly
investigated translocation rates following Resveratrol, Simvastatin,
or Curcumin treatment. Bacterial translocation into MLNs was
detected in all animals at day 8 p.i.. (Fig. 8 A). Living bacteria
translocated into the spleen in 78.1%, 57.1%, 55.6%, or 33.3% of
cases after treatment with Placebo, Resveratrol, Simvastatin, or
Curcumin, respectively (Fig. 8 B). The translocation rates into
liver (Fig. 8 C) and kidney (Fig. 8 D) were much lower in
Resveratrol- (57.1% and 42.9%, respectively) and Curcumin-
(55.6% and 22.2%, respectively) treated animals as compared to
the Placebo (77.8% and 66.7%, respectively) and Simvastatin
(77.8% and 66.7%, respectively) groups. Oral treatment with
Simvastatin (22.2%) or Curcumin (11.1%) resulted in less frequent
bacteremia (and thus subsequently less frequent potential lethal
sepsis) as compared to Placebo controls (29.6%) at d8 p.i. (Fig. 8
E). Surprisingly, all blood samples taken from Resveratrol treated
mice bacteria remained sterile. The translocating bacterial species
that could be cultured from the organs were predominantly E. coli
and enterococci, the bacterial groups that were overgrowing the
ileum lumen during ileitis as described above. No living bacteria
could be cultured from the respective organs of naı ¨ve (non-
infected, untreated) mice with intact small intestinal barrier
function.
Thus, Simvastatin, Curcumin and Resveratrol treatment
remarkably reduced bacterial translocation into subepithelial
tissues thereby minimizing bacteria/TLR ligation and preventing
immune cell activation and subsequent inflammatory response
initiation.
Discussion
Inflammatory bowel diseases (IBD) such as Crohn’s disease (also
termed ileitis terminalis) and ulcerative colitis are characterized by
chronic intestinal inflammation with acute episodes of multi-
factorial etiology [18,19]. The vast majority of experimental
studies concerning intestinal inflammation have been performed in
murine models affecting the colon. Thus, we used our well-
established, hyper-acute model of small intestinal inflammation
following T. gondii infection to investigate anti-inflammatory and
immuno-modulatory effects of Resveratrol, Curcumin, and
Simvastatin in ileal inflammation. The immunopathology ob-
served after T. gondii infection is driven by Th1 cells and by the
bacterial gut flora. This situation resembles immunopathology
during acute episodes of Crohn’s disease [20]. Furthermore, the
underlying immunopathology is characterized by an overproduc-
tion of pro-inflammatory cytokines such as IL-12, IFN-c, TNF-a,
and IL-23, a key regulator of the immune response cascade
[12,13,21].
Here, we demonstrate that hyper-acute inflammation in the
small intestine is ameliorated by either Resveratrol, Curcumin or
Simvastatin treatment. In addition, the anti-inflammatory effects
of the compounds under investigation during the acute phase of
ileitis (on day 8 after ileitis induction by peroral infection with T.
gondii) were comparable: animals from all three treatment groups
were protected from immunopathology development and exhib-
ited better clinical conditions, less body weight loss and shortening
of the small intestinal length. Untreated mice also displayed severe
pan-ileitis whereas treated animals (irrespective of the compound
used) only showed minor mucosal changes with an intact epithelial
lining. Furthermore, reduced ileal inflammation in Resveratrol
and Curcumin treated mice might result from compensatory
higher proliferation rates of intestinal epithelial cells found in the
ileal mucosa as shown by higher Ki67
+ cell numbers after
respective treatment.
Moreover, the amelioration of immunopathology was accom-
panied by a reduced accumulation of CD3
+ T lymphocytes as well
as lower expression of the key regulator IL-23 and pro-
inflammatory cytokines IFN-c and TNF-a in the small intestinal
lamina propria after Resveratrol or Curcumin treatment.
Furthermore, ileal secretion of IFN-c and the monocyte
chemotactic protein MCP-1 was significantly decreased after
treatment with Simvastatin, Resveratrol, or Curcumin. In parallel,
myeloperoxidase-7
+ neutrophilic granulocytes recruitment was
diminished thereby limiting oxidative stress in the ileum and
maintaining an integral epithelial cell barrier function. In addition,
numbers of FOXP3
+ cells were diminished in untreated mice, but
significantly increased (comparable to the observed numbers in
naı ¨ve mice) in treated animals after ileitis induction which
correlates with increased concentrations of the anti-inflammatory
cytokine IL-10 observed in ileum, MLNs, and spleen at d8 p.i..
Figure 6. IL-10 concentrations (CBA-ELISA) in supernatants of Ileum (A), MLN (B) and spleen (C) cultures from naı ¨ve, uninfected
animals and mice treated with Simvastatin (SIMVA), Resveratrol (RESVE) or Curcumin (CURCU) from d-2 until d8 p.i. as compared
to Placebo controls (8 days after T. gondii infection). Numbers of analyzed animals are given in parentheses. Mean values, standard errors of
the mean, and significance levels as indicated were determined by the Student’s t test. Data are pooled from at least two independent experiments.
doi:10.1371/journal.pone.0015099.g006
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inflammatory responses in a cholesterol-independent manner by
interfering with endothelial adhesion and leukocyte migration to
sites of inflammation [11,22]. In rats with normal blood
cholesterol levels, simvastatin was found to ameliorate immuno-
pathology in an acute TNBS colitis model by blocking neutrophil
accumulation in the small intestine and lowering serum TNF-a
levels [23].
Curcumin exerts its anti-inflammatory effects in murine colitis
models by inhibiting COX2- and pro-inflammatory cytokine
expression such as nitric oxide [9,24,25] and suppressing NF-kB
activation [26,27].
Figure 7. Changes in the composition of the luminal ileum flora obtained from uninfected animals (none) and T. gondii-infected
mice treated with Simvastain (SIMVA), Resveratrol (RESVE) or Curcumin (CURCU) from d-2 until d8 p.i. as compared to Placebo
controls (8 days after T. gondii infection). Detailed cultural analysis was performed on appropriate selective media, bacterial species identified by
biochemical analysis and reconfirmed by comparative sequence analysis (see Methods). Individual bacterial counts (CFU, colony forming units) of (A)
Total bacterial load, (B) E. coli,( C) enterococci, (D) lactobacilli/bifidobacteria obtained from respectively treated mice (numbers of animals are given in
parentheses), medians and levels of significance determined by Mann-Whitney-U test are indicated. Data are pooled from two representative
experiments.
doi:10.1371/journal.pone.0015099.g007
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and IL-1b production as well as an enhanced apoptosis of colonic
mucosa was observed following Resveratrol treatment [28]. In
chronic DSS-induced colitis, both decreased expression of pro-
inflammatory cytokines (TNF-a, NO, and IL-1b) and increased
anti-inflammatory mediators (IL-10) in the colonic mucosa
contributed to attenuate inflammation after Resveratrol treatment
[29]. In addition, even low dose Resveratrol treatment exerted
anti-inflammatory effects in an acute DSS-induced colitis model
by reducing expression levels of prostaglandin-E2, COX2, and
NO [6].
Changes in commensal gut flora composition observed in acute
T. gondii-induced ileitis resemble the gut flora changes found in
humans with IBD [14,15]. Shifts in the ileal flora composition
become overt around d5 p.i., the time point when first significant
defects of the epithelial barrier are histologically detectable. Ileitis
development is accompanied by decreased species diversity,
decreased loads of potentially anti-inflammatory species such as
lactobacilli and bifidobacteria and a marked increase in commen-
sal, potentially pro-inflammatory E. coli in the ileum lumen by 6–8
orders of magnitude. Furthermore, overgrowing E. coli within the
gut aggravates Toll-like receptor- (TLR-) 4 driven immune
responses during T. gondii-induced ileitis [15]. In addition,
overgrowing bacteria easily translocate through a disrupted
epithelial cell barrier into the intestinal lamina propria, lymphoid
tissues (e.g. the ileum draining MLNs) and subsequently come in
contact with immune cells thereby exacerbating intestinal
inflammation. Lastly, when translocating bacteria reach the
systemic blood stream, peritonitis, sepsis and subsequent multiple
organ failure occurs with fatal consequences [14,15]. Therefore,
we investigated whether Simvastatin, Resveratrol or Curcumin
could prevent gut flora composition changes and bacterial
translocation after T. gondii infection. Interestingly, treatment with
either compound significantly diminished total bacterial ileal
burdens as compared to untreated animals. Strikingly, lower E. coli
and enterococci counts were found in treated mice whereas
lactobacilli and bifidobacteria populations were slightly but
significantly increased. In addition, ileitis development is accom-
panied by a marked decrease in the lactobacilli and bifidobacteria
populations [14] and strikingly, after either treatment these
lactobacilli and bifidobacteria populations remained at compara-
ble levels with naı ¨ve, uninfected mice. Remarkably, none of the
compounds had a direct anti-microbial effect in vitro.
Larrosa and co-workers reported in 2009 similar flora shifts in
an acute DSS-induced colitis model, however, to a much lesser
extent: After low-dose Resveratrol treatment, rats exhibited
increases in lactobacilli and bifidobacteria populations within the
colonic lumen and blocked the increase in enterobacteria (mainly
E. coli) [6]. In several studies, a protective effect of lactobacilli and
bifidobacteria in DSS-colitis could be demonstrated [30], as well
as modulatory effects upon pro-inflammatory responses in
intestinal epithelial cells that have been challenged with patho-
genic enterobacteria [31]. Thus, abundance of anti-inflammatory
lactobacilli and bifidobacteria together with scarcity of pro-
Figure 8. Bacterial translocation into (A) MLN, (B) Spleen, (C) Liver, (D) Kidney, and (E) Blood of mice treated with Simvastain
(SIMVA), Resveratrol (RESVE) or Curcumin (CURCU) from d-2 until d8 p.i. as compared to Placebo controls (8 days after T. gondii
infection). Organs or blood were cultivated in thioglycolate broth for maximum 7 days. Turbid broths were sub-cultivated on solid media (refer to
Materials). Indicated are relative rates of positive samples (in %) and absolute numbers of positive samples out of total number analyzed in
parentheses.
doi:10.1371/journal.pone.0015099.g008
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ileitis.
Resveratrol, Simvastatin, or Curcumin treatment might have an
anti-inflammatory effect by directly interfering with the TLR/
MyD88 signaling pathway. Recent findings in acute TNBS-
induced colitis model in rats demonstrate that Curcumin-induced
inhibition of intestinal inflammation involves TLR-4 and MyD88
[32].
Furthermore, an effect of Curcumin on matrixmetalloprotei-
nases (MMPs; important in the pathogenesis of human IBD [33])
was recently described [34]: Curcumin down-regulated MMP-9
(gelatinase-B) activity on inflammation-induced intestinal epithelial
cells in vitro. We have recently shown that non-selective MMP- as
well as selective gelatinase blockage by a synthetic compound
ameliorated T. gondii ileitis [12]. However, MMP-2, but not MMP-
9 played a crucial role in mediating small intestinal pathology.
MMP-9 is proposed to play an important role in experimental
colitis [35]. Interestingly, neutrophils have been proposed as an
important source for MMPs. Thus, inhibition of neutrophil
migration by the investigated compounds might also down-
modulated MMP secretion thereby diminishing epithelial cell
inflammation.
In a recent study, Curcumin has been shown to inhibit oxidative
stress [36] that in turn has been associated with tight junction
opening, thereby modifying intestinal permeability [37]. In the
present study, bacterial translocation rates (due to compromised
epithelial barrier function) into spleen and cardiac blood after
treatment with either compound were lower as compared to the
Placebo group. Therefore, Resveratrol, Simvastatin, and Curcu-
min might modulate tight junction protein expression and
function.
Most strikingly, 20 to 40% of the animals treated with
Resveratrol, Simvastatin, or Curcumin survived the acute phase
of inflammation whereas all untreated mice had died at d11 p.i.. In
addition, 40% of Resveratrol treated mice displayed a long-term
survival (until the end of the observation period until d19 p.i.;
p,0.005 vs. Placebo). The long-term survival effect of Resveratrol
is remarkable for three reasons: First, in our study, the duration of
treatment (before and during course of acute inflammation) was
rather short: Resveratrol treatment was initiated two days prior to
ileitis induction and lasted 10 days in total; at d8 p.i. treatment was
withdrawn. Second, given that the bioavailibility of the compound
is low, short-term and local rather than systemic effects are
observed within the gut lumen (effective until d8/d9 p.i.). Because
T. gondii-induced ileitis compromises the intestinal absorption
capacity, Resveratrol absorption after oral application is also
reduced. Third, Resveratrol treatment improves survival in a
hyper-acute small intestinal inflammation model where all Placebo
control mice died. Thus far, Resveratrol treatment has only been
shown to reduce mortality in a chronic colitis model [29]. We
might hypothesize that Resveratrol treatment prevents bacterial
translocation into the systemic circulation because in our study, we
did not observe bacterial growth in any of blood cultures drawn
from Resveratrol treated mice. Therefore, mice are protected from
a bacteremia-induced sepsis that leads to death. Furthermore,
fewer bacteria translocation rates into sub-epithelial tissues might
be due to a less compromised epithelial barrier function. Fewer
translocation rates are mirrored by an IL-6 decrease in the ileum
of Resveratrol treated animals. Our findings agree with those in
the literature suggesting that genes belonging to the IL-6 pathway
are down-regulated in Resveratrol treated mice in experimental
colitis [6] and other inflammation models [38].
In conclusion, here we show for the first time that Resveratrol,
Curcumin, and Simvastatin exert potent anti-inflammatory effects
in a hyper-acute Th1-type driven small intestinal inflammation
model. In addition, Resveratrol, Curcumin, and Simvastatin
represent novel and promising intervention strategies for prophy-
laxis and therapy of small intestinal inflammation in IBD.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to the
German animal protection laws (LaGeSo Berlin, TVV G0145/
10 and G0146/10) with approval from the Charite ´ – Universi-
ta ¨tsmedizin ethical committee. Animal welfare was monitored
twice daily by assessment of clinical conditions and weight loss of
mice.
Mice, parasites and ileitis induction
C57BL/10ScSn (wildtype) mice used for experiments were 3
months old and bred under specific pathogen-free (SPF) conditions
in the Forschungsinstitut fu ¨r Experimentelle Medizin (Charite ´,
Berlin, Germany). For induction of ileitis, mice were infected
orally with 100 T. gondii cysts (ME49 strain) from homogenized
brains of intraperitoneally infected NMRI mice in a volume of
0.3 ml phosphate-buffered saline (PBS, pH 7.4) by gavage, as
described previously [14].
Compounds
Resveratrol, Curcumin, and Simvastatin were dissolved in 2%
Carboxy-Methyl-Cellulose (in PBS; all purchased from Sigma-
Aldrich, Mu ¨nchen, Germany) and administered to mice with a
daily dose of 20 mg, 100 mg, and 20 mg per kg body weight,
respectively. Mice received the respective verum compound or the
carrier solution (serving as Placebo control) perorally by gavage (in
a 0.3 ml volume) once daily starting 2 days before T. gondii
infection until the end of the experiment at day (d) 8 post infection
(p.i.).
Sampling procedures and determination of small
intestinal shortening
Mice were sacrificed by isoflurane 8 days after infection (Abbott,
Wiesbaden, Germany). Cardiac blood and tissue samples from
liver, spleen, kidneys, mesenteric lymph nodes and terminal ileum
were removed under sterile conditions. Intestinal samples from
each mouse were collected in parallel for histological, microbio-
logical, immunological and molecular analyses. The relative
shortening of the small intestine was calculated by dividing the
difference of the mean length of small intestine from age- and sex-
matched naı ¨ve control mice minus the length of infected mice at
day 8 p.i. and then multiplied by 100 over the mean length of
naı ¨ve control mice small intestines (relative shortening in length =
(mean d0 – d8 p.i.)6100/mean d0). Results were expressed as %
shortage.
Histologic scores and determination of parasite load
Histologic scores of ileitis and parasite loads were determined in
tissue samples from terminal ileum immediately fixed in 5%
formalin and embedded in paraffin as described earlier [14,15].
Sections (5 mm) were stained with hematoxylin and eosin and
examined by light microscopy. Our standardized histological
inflammation score ranging from 0 to 6 (0, normal; 1, edematous
blubbing; 2, cell-free exudate into the lumen, but intact
epithelium; 3, cellular shedding into the lumen; 4, beginning
epithelial disintegration; 5, mucosal destruction ,50% of small
intestine length; 6, complete destruction .50% of small intestine
Resveratrol, Curcumin, Simvastatin Prevent Ileitis
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(by M.M.H. and M.M.). Numbers of parasitophorous vacuoles
containing tachyzoites or tachyzoite antigens were determined by
immunohistology using a rabbit anti-T. gondii- IgG antiserum and
counted in the terminal ileum, as previously described [21]. In
addition, T. gondii DNA in ileal biospies was quantified as
described earlier [12].
Immunohistochemistry
In situ immunohistochemical analysis of ileum paraffin sections
were performed as described previously [39]. Primary antibodies
against CD3 (# N1580, Dako, Glostrup, Denmark, dilution 1:10),
FOXP3 (FJK-16s, eBioscience, San Diego, USA, 1:100), myelo-
peroxidase-7 (MPO7, # A0398, Dako, 1:500), and Ki-67 (TEC3,
Dako, 1:100) were used. For each animal, the average number of
positive stained cells within at least six independent high power
fields (HPF, high power visual field in 4006magnification) were
determined microscopically by two independent investigators
(M.M.H. and C.L.) and subjected to statistical analysis as
indicated.
Real-time PCR
RNA was isolated from organs, reverse transcribed and
analyzed as described previously [12]. Mouse IL-23p19, IFN-c
and TNF-a mRNA expressions were detected and analyzed using
Light Cycler Data Analysis Software, Roche. Expression levels
were calculated relative to the HPRT expression (and indicated as
‘‘Arbitrary Units’’).
Cytokine detection in ileum, MLN, and spleen culture
supernatants
Ileum biopsies were cut longitudinally, washed with PBS and
strips of 1 cm
2, MLNs or spleen placed in 24-flat-bottom well
culture plates (Nunc, Wiesbaden, Germany) containing 500 ml
serum-free RPMI 1640 medium supplemented with penicillin
(100 U/ml) and streptomycin (100 mg/ml; PAA Laboratories).
After 18 h at 37uC, culture supernatants were tested for IFN-c,
MCP-1, and IL-10 concentrations by the Mouse Inflammation
Cytometric Bead Array (CBA; BD Biosciences).
Cultural analysis of the ileum microflora and bacterial
translocation
Culture-based analysis of the ileum flora was performed as
described earlier [14]. For qualitative detection of bacterial
translocation, cardiac blood (approx. 0.5 ml) or the respective
organ (liver, spleen, MLN, kidney) was immediately transferred
into thioglycolate broth under sterile conditions and incubated for
maximum 7 days at 37uC. Bacterial growth was monitored daily
by turbidity assessment. Aliquots from turbid broths were
cultivated on solid media under aerobic, microaerophilic and
obligate anaerobic conditions and the bacterial species identified
microbiologically and biochemically as described earlier [14].
Antimicrobial effects of Simvastatin, Curcumin and Resveratrol
were assessed in vitro by inoculating a blank susceptibility disk
(Oxoid, Basingstoke, UK) with 10 ml of either compound. Before,
the blank disc was placed onto an Mu ¨ller-Hinton agar plate
(Oxoid) that was inoculated with a highly susceptible Bacillus subtilis
ATCC 6633 strain. After overnight incubation (37uC), lack of
growth inhibition around the disk was indicating a negative
antimicrobial result [40].
Statistical analysis
Mean values, medians, standard deviations, standard errors of
the mean, and levels of significance were determined using
appropriate tests as indicated (Student’s t-Test, Mann-Whitney U-
Test or the log-rank test for Kaplan-Meier analysis of survival).
Two-sided probability (p) values #0.05 were considered signifi-
cant. All experiments were repeated at least twice.
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